Pancreatic cancer has been shown to be among the most immunotolerant types of tumours, with clinical trials showing unsatisfactory results and poor response to PD-1/PD-L1 blockade monotherapy [9, 10]. The gene discussed is PDCD1; the disease is neoplasm.